Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase IV Post-Approval Safety Study of ELPIDA®

Trial Profile

A phase IV Post-Approval Safety Study of ELPIDA®

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Jan 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elsulfavirine (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Adverse reactions

Most Recent Events

  • 07 Jan 2019 New trial record
  • 21 Dec 2018 According to a Viriom media release, to date 300 of planned 2000 patients have completed 24 weeks of treatment in this study. Additional clinical studies have been initiated to assess safety and efficacy of Elpida in HIV-infected persons with comorbidities and when co-administered with other drugs.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top